Introduction

ReLIA Biotechnologies (Jiangsu), Inc. is a wholly-owned subsidiary of ReLIA Diagnostic Systems, USA. The company was founded in China Medical City (CMC), Taizhou, China in 2010, with registered capital of 2.3 million USD and total investment of 4.6 million USD.

ReLIA Diagnostic Systems has developed a low-cost, high-performance portable immunoassay system for point-of-care (POC) diagnosis that provides high sensitivity, precision, accuracy and reliability of expensive and complex central laboratory systems, with the advantage of bedside testing.

Its state-of-art manufacturing facility has received GMP certification from Chinese SFDA for manufacturing medical device and diagnostic reagent products. It also provides market with products that CE-marked.


一、公司简介
瑞莱生物科技（江苏）有限公司是美国著名的ReLIA生物医疗诊断公司在中国的独资企业，于2010年在江苏泰州中国医药城成立，注册资金230万美元，投资总额超过460万美元。
瑞莱公司主要从事体外诊断试剂，特别是即时检验技术（POCT）产品的研发、生产及销售，研制开发出具有国际自主知识产权的ReLIA 多功能免疫检测系统。现公司已经获得：国家食品药品监督管理局(SFDA)颁发的《医疗器械生产许可证》、欧盟的CE认证，公司最终将通过美国的FDA认证。
ReLIA 多功能免疫检测系统具备了“快速、定量、全血检测、使用简便”等即时检验技术的必备条件，是国内率先拥有国际自主知识产权的POCT技术产品。